%PDF-1.4
%
35 0 obj
<>
endobj
31 0 obj
<>
endobj
89 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2003-01-07T18:40:25Z
2024-03-28T12:30-07:00
2024-03-28T12:30-07:00
QuarkXPress. 4.11: AdobePS 8.6 (219)
application/pdf
Heather
2002-295.feb
uuid:a1900ba3-1dd1-11b2-0a00-b70827edca00
uuid:a1900ba5-1dd1-11b2-0a00-380000000000
endstream
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
97 0 obj
[101 0 R]
endobj
98 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
440 777 117 -27 re
f
54 54 m
558 54 l
S
BT
0 g
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:2)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(406)Tj
ET
1 g
109.5 58.85 395.97 -10.34 re
f
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 g
/T1_1 1 Tf
-0.00011 Tc 0.1295 Tw 9.7 0 0 10 54 713.1616 Tm
[(tivity in RA)-324.6 (and also restores normal responses of lympho-)]TJ
0.1347 Tw 0 -1.2 TD
(cytes to various stimuli )Tj
/T1_0 1 Tf
[-0.4 (ex vivo)]TJ
/T1_1 1 Tf
0.0005 Tc 0 Tw 6.3 0 0 6.5 180.3958 704.4616 Tm
(13,14)Tj
-0.00011 Tc 0.1347 Tw 9.7 0 0 10 194.582 701.1616 Tm
[(. Recently)64.8 (, it was shown)]TJ
0.311 Tw -14.493 -1.2 Td
(that salazosulfapyridine enhances adenosine release at an)Tj
0.02499 Tw T*
(inflamed site in the same fashion as MTX)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 218.116 680.4615 Tm
(15)Tj
0 Tc 9.7 0 0 10 224.4209 677.1616 Tm
(.)Tj
-0.00011 Tc -0.0015 Tw -16.3321 -1.2 Td
(These pharmacologic features seem to justify a therapeutic)Tj
0.0471 Tw -1.2371 -1.2 Td
[(trial of this drug in patients with Felty\325)54.9 (s syndrome because it)]TJ
0.0703 Tw T*
[(is characterized by hyper)19.7 (-autoimmunity in patients with RA.)]TJ
-0.08 Tc 0 Tw T*
[(We)-79.9 ( )]TJ
-0.00011 Tc 0.0764 Tw 1.6343 0 Td
(selected low dose salazosulfapyridine as the initial treat-)Tj
0.2038 Tw -1.6343 -1.2 Td
(ment for our patient and found it increased the neutrophil)Tj
0.29449 Tw T*
[(count. )54.8 (Also, it clearly showed immunomodulatory ef)17.7 (fects)]TJ
0.08369 Tw T*
(because it suppressed at least several autoantibodies, includ-)Tj
0.02499 Tw T*
[(ing antineutrophil and antiplatelet antibodies, and RF)79.7 (.)]TJ
-0.03239 Tw 1.2371 -1.2 Td
(Low dose MTX is the most widely prescribed treatment for)Tj
0.013 Tw -1.2371 -1.2 Td
[(RA, and it is the anchor drug in several dif)17.7 (ferent combination)]TJ
0.00079 Tw T*
[(therapies. However)39.7 (, MTX has side ef)17.7 (fects, such as hepatotox-)]TJ
0.224 Tw T*
[(icity)64.8 (, acute interstitial pneumonitis, gastrointestinal intoler-)]TJ
0.15601 Tw T*
[(ance, and hematopoietic suppression. )17.8 (When patients cannot)]TJ
0.14729 Tw T*
(tolerate MTX, low dose salazosulfapyridine is a reasonable)Tj
0.02499 Tw T*
[(alternative for treatment of Felty\325)54.8 (s syndrome.)]TJ
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 463.1616 Tm
[(1.)-875.1 (Felty )54.8 (AR. Chronic arthritis in the adult, associated with)]TJ
1.675 -1.25 Td
(splenomegaly and leukopenia. Bull Johns Hopkins Hosp)Tj
0 Tc 0 Tw 0 -1.25 TD
(1926;395:16-20.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia)]TJ
1.675 -1.25 Td
[(with methotrexate treatment in patients with Felty\325)54.8 (s syndrome.)]TJ
T*
[(Correlation of response with neutrophil-reactive IgG. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1989;32:194-201.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (W)79.9 (assenber)17.7 (g S, Herborn G, Rau R. Methotrexate treatment in)]TJ
1.675 -1.25 Td
[(Felty\325)54.8 (s syndrome. Br J Rheumatol 1998;37:908-1)36.8 (1.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (T)69.9 (alip F)79.7 (,)-0.1 ( )17.7 (W)79.9 (alker N, Khan )17.7 (W)91.9 (, Zimmermann B. )17.7 (T)35 (reatment of Felty\325)54.8 (s)]TJ
1.675 -1.25 Td
(syndrome with leflunomide. J Rheumatol 2001;28:868-70.)Tj
31.325 43.921 Td
[(5.)-875.1 (Joseph G, Neustadt DH, Hamm J, Kellihan M, Hadley )17.7 (T)74 (. GM-CSF)]TJ
1.675 -1.25 Td
[(in the treatment of Felty syndrome. )54.8 (Am J Hematol 1991;37:55-6.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Logue G. Felty\325)54.8 (s syndrome: granulocyte-bound immunoglobulin G)]TJ
1.675 -1.25 Td
[(and splenectomy)64.8 (. )54.8 (Ann Intern Med 1976;85:437-42. )]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Starkebaum G, Singer JW)91.7 (, )54.8 (Arend )17.7 (WP)110.7 (. Humoral and cellular)]TJ
1.675 -1.25 Td
[(immune mechanisms of neutropenia in patients with Felty\325)54.8 (s)]TJ
T*
(syndrome. Clin Exp Immunol 1980;39:307-14.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Breedveld FC, Lafeber GJ, de )17.7 (V)59.8 (ries E, van Krieken JH, Cats )54.8 (A.)]TJ
1.675 -1.25 Td
[(Immune complexes and the pathogenesis of neutropenia in Felty\325)54.8 (s)]TJ
0 Tc T*
[(syndrome. )54.9 (Ann Rheum Dis 1986;45:696-702.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Ditzel HJ, Masaki )36.8 (Y)128.9 (, Nielsen H, Farnaes L, Burton DR. Cloning)]TJ
1.675 -1.25 Td
(and expression of a novel human antibody-antigen pair associated)Tj
T*
[(with Felty\325)54.8 (s syndrome. Proc Natl )54.8 (Acad Sci USA)-220.2 (2000;97:9234-9.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Farr M, )17.7 (T)35 (unn EJ, Symmons DP)110.7 (, Scott DG, Bacon P)91.7 (A.)]TJ
2.175 -1.25 Td
(Sulphasalazine in rheumatoid arthritis: haematological problems)Tj
T*
[(and changes in haematological indices associated with therapy)64.8 (. Br J)]TJ
T*
(Rheumatol 1989;28:134-8.)Tj
-0.0369 Tc 0 Tw -2.1381 -1.25 Td
(11)Tj
0.875 Tc 0.9631 0 Td
(.T)Tj
-0.00011 Tc 0.02499 Tw 1.7009 0 Td
[(unn EJ, Farr M, Scott DGJ, Symmons DPM, Bacon P)91.7 (A.)]TJ
-0.5259 -1.25 Td
[(Sulphasalazine and Felty\325)54.8 (s syndrome \321 haematological problems.)]TJ
T*
(Br J Rheumatol 1986;25 Suppl 2:48.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Dougados M, Combe B, Cantagrel )54.8 (A, et al. Combination therapy in)]TJ
2.175 -1.25 Td
(early rheumatoid arthritis: a randomised, controlled, double blind)Tj
T*
(52 week clinical trial of sulphasalazine and methotrexate compared)Tj
T*
[(with the single components. )54.8 (Ann Rheum Dis 1990;58:220-5.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Imai F)79.7 (,)-0.1 ( Suzuki )17.7 (T)74 (, Ishibashi )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (anaka M, )54.8 (Akiyama )36.8 (Y)128.9 (,)-0.1 ( Dohi )36.8 (Y)128.9 (. Ef)17.7 (fect)]TJ
2.175 -1.25 Td
(of sulfasalazine on B cell hyperactivity in patients with rheumatoid)Tj
T*
(arthritis. J Rheumatol 1994;21:612-5.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Samanta )54.8 (A, )17.7 (W)79.9 (ebb C, Grindulis KA, Fleming J, Sheldon PJ.)]TJ
2.175 -1.25 Td
(Sulphasalazine therapy in rheumatoid arthritis: qualitative changes)Tj
T*
(in lymphocytes and correlation with clinical response. Br J)Tj
T*
(Rheumatol 1992;31:259-63.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Gadangi P)110.7 (, Longaker M, Naime D, et al. )17.7 (The anti-inflammatory)]TJ
2.175 -1.25 Td
(mechanism of sulfasalazine is related to adenosine release at)Tj
T*
(inflamed sites. J Immunol 1996;156:1937-41.)Tj
ET
1 g
438 770 120 -25 re
f
BT
0 g
/T1_3 1 Tf
0 Tw 20.37 0 0 21 461.9631 753.6089 Tm
(2002-295-3)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS1 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS1 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS1 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS1 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
99 0 obj
<>
endobj
42 0 obj
<>
endobj
47 0 obj
<>
endobj
51 0 obj
<>
endobj
40 0 obj
<>
endobj
82 0 obj
<>
endobj
93 0 obj
<>
endobj
44 0 obj
<>
endobj
39 0 obj
<>
endobj
41 0 obj
<>stream
HTMO0>qH0ei>,uG%Fiwؿǎ&OcWovgoqt{}q!{h{7_Oiu
IL3;ߍ4J4,kl1CI9oϐz
-vJomxfٟp E:cS'ЬhAS8vF%YFq+%.i#^ +*1
?6S|(5-єTW9q%b2lĪYK VM͒Z*YR;b#O7\KŰİb-PJ^ omwi"iʩGc~ je
endstream
endobj
43 0 obj
<>stream
H\T{PSwڀa^VVTVEEy#Ly^ $!$HHycx!*Q)j[-ݭ֭z3{Μ3s99}P(.B||>=Kd
2xU A<)ȗ "H4RP7"ۑȡ5~(Ftj)EO#"#'J1*]pn﴾뽽ka^<-F>ˉliEC\E"ooX7,#ם+ FkXsI&^380={
%\ WDw3Dl1wm-Sׁi7m(t-lKFOFvNhD1aGp̞`B_z5z/bfۣY7]%fۙޒm F$@ISMƸ Ǝ$"]_xIpM }$OOk{3V,ިcjVjK
U[]*NVTmU[!JJ(E**TEu
i~lh\ [Cu:I(7*գ@XtNA3p6$K"ܼg
e2Wfya :^vc,=S?xՐE̪'36ugjTwe4*Ol5б2n+d
i۾_B'IӜ^raUO,
ߗxvYmm]-͠ipn{z'刍NH'drbB{dkdxb0'4sE
`1r[~a{Ll-v_B'.,ssec1wOkLwkD} ¤j6qefI3uh91xL88+''x4m$"9